Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cathia Rene

Gastroenterology Lake Worth, FL Medical Doctor

NPI 1306928924 CMS profile 58849

5065 South State Road 7, Suite 201, Lake Worth, FL 33449

Open in the dashboard

General payments

$7,984

357 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cathia Rene of Lake Worth, FL is reported in the CMS Open Payments database as having received $7,984 across 357 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,422 71
2024 General $2,210 73
2023 General $1,188 56
2022 General $1,397 49
2021 General $694 46
2020 General $342 16
2019 General $732 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cathia Rene
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Cathia Rene were reported at $1,422. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Cathia Rene Gastroenterology median Middle half National median
2019 $732 $417 $126–$1,100 $163
2020 $342 $224 $74–$624 $114
2021 $694 $352 $106–$1,054 $132
2022 $1,397 $448 $129–$1,270 $149
2023 $1,188 $533 $150–$1,390 $160
2024 $2,210 $605 $160–$1,606 $164
2025 $1,422 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $2,193 19 payments
  2. AbbVie, Inc. $1,739 132 payments
  3. Janssen Biotech, Inc. $1,317 70 payments
  4. Gilead Sciences, Inc. $484 23 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $305 15 payments
  6. Pfizer Inc. $293 19 payments
  7. Phathom Pharmaceuticals, Inc. $187 5 payments
  8. Celgene Corporation $162 9 payments
  9. Ardelyx, Inc. $139 5 payments
  10. Celltrion USA Inc. $102 4 payments
  11. Other $1,063 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,512 346 payments
  2. Travel and Lodging $1,163 7 payments
  3. Education $309 4 payments
Products named General payments · program years 2019–2025
  1. INTERSTIM $2,173 18 payments
  2. STELARA $802 40 payments
  3. LINZESS $567 52 payments
  4. TREMFYA $515 30 payments
  5. CREON $478 39 payments
  6. MAVYRET $375 24 payments
  7. HUMIRA $296 19 payments
  8. RINVOQ $282 21 payments
  9. XELJANZ $278 18 payments
  10. ZEPOSIA $162 9 payments
  11. Other $2,544 137 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,092

Median for Gastroenterology: 569

Drug cost

$608,824

Median for Gastroenterology: $104,976

Branded share of claims

23.4%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 18 $473,688
Linzess Linaclotide Brand 74 $85,455
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 82 $13,848
Sucralfate Generic 37 $9,445
Omeprazole Generic 315 $4,289
Mesalamine Dr Mesalamine Brand 11 $4,169
Colesevelam Hcl Generic 21 $3,644
Dicyclomine Hcl Generic 68 $2,746
Cholestyramine Cholestyramine (With Sugar) Brand 20 $2,469
Mesalamine Er Mesalamine Brand 17 $2,050

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$56,076

Medicare's payments for the services billed

Medicare patients

235

Average age 73

Services billed

523

185 women, 50 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 55%
Diabetes 30%
Ischemic heart disease 30%
Chronic kidney disease 30%
Osteoporosis 26%
Depression 23%
Cancer 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $271
$271 18 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $163
$163 — —
TREMFYA
  • Janssen Biotech, Inc. $90
$90 — —
LINZESS
  • AbbVie, Inc. $81
$81 74 —
VEGZELMA
  • Celltrion USA Inc. $73
$73 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

357 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record